|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| General and administrative expenses | ||||
| Research and development expenses | ||||
| Selling and marketing expenses | ||||
| Impairment and amortization | ||||
| Listing expenses | ||||
| Operating loss | ||||
| Finance income | ||||
| Gain from remeasurement of investment in associated company | ||||
| Share of net profit (loss) of associated companies | ||||
| Loss before income tax | ||||
| Net loss | ||||
| Adjustments arising from translating financial statements from functional currency to presentation currency | ||||
| Exchange losses arising on translation of foreign operations | ||||
| Other comprehensive loss: | ||||
| Total comprehensive loss | ||||
| Net loss attributable to: | ||||
| Equity holders of the Company | ||||
| Non- controlling interest | ||||
| Basic loss per share attributable to shareholders | ||||
| Diluted loss per share attributable to shareholders | ||||
Loading...